Search

Your search keyword '"Škorňová, Ingrid"' showing total 144 results
Start Over Author "Škorňová, Ingrid"
144 results on '"Škorňová, Ingrid"'

2. Cytokines in Renal Cell Carcinoma: A Step Towards Earlier Detection and Targeted Therapy

Author

Vargová, Daniela, Ľupták, Ján, Dargaj, Ján, Fraňová, Soňa, Kocmálová, Michaela, Šutovský, Juraj, Švihra, Ján, Sr, Škorňová, Ingrid, Slávik, Pavol, Grendár, Marián, Švihra, Ján, Jr, Briš, Lukáš, Šutovská, Martina, Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, Steinlein, Ortrud, Series Editor, Xiao, Junjie, Series Editor, and Pokorski, Mieczyslaw, editor

Published
2022
Full Text
View/download PDF

3. High On-Treatment Platelet Reactivity in Patients Undergoing Complex Percutaneous Coronary Interventions

Author

Lukáš Urban MD, PhD, Škorňová Ingrid Ing, PhD, Jana Žolková Ing, PhD, Staško Ján MD, PhD, Tomáš Bolek MD, PhD, and Matej Samoš MD, PhD

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Patient response to P2Y12 inhibitor therapy is heterogeneous, and those with high on-treatment platelet reactivity (HTPR) are at an increased risk of thrombotic complications. The aim of our study was to determine whether selecting a high-risk patient group of individuals after complex percutaneous coronary intervention (PCI) would show the clinical benefit of HTPR testing for preventing thrombotic complications. Blood samples of patients after complex PCI were acquired 1 day and 1 month after the intervention. The samples were tested using vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) and platelet function assay (PFA). The occurrence of clinically significant stent thrombosis with repeated revascularization of the target vessel was observed over a 1-year period. One day after PCI, 37% of patients had HTPR as established by VASP-P. One month after PCI, the percentage of patients with HTPR decreased to 30.9%. According to PFA, 1 day after PCI, 33.3% of patients had HTPR. This percentage declined to 19.8% after 1 month. All measurements identified a significantly higher proportion of HTPR in patients on clopidogrel compared to ticagrelor and prasugrel. Two cases of early stent thrombosis and 1 case of late stent thrombosis were identified. Further study of adenosine diphosphate receptor blocker on-treatment response in patients undergoing complex PCI is necessary.

Published
2023
Full Text
View/download PDF

5. Cytokines in Renal Cell Carcinoma: A Step Towards Earlier Detection and Targeted Therapy

Author

Vargová, Daniela, primary, Ľupták, Ján, additional, Dargaj, Ján, additional, Fraňová, Soňa, additional, Kocmálová, Michaela, additional, Šutovský, Juraj, additional, Švihra, Ján, additional, Škorňová, Ingrid, additional, Slávik, Pavol, additional, Grendár, Marián, additional, Briš, Lukáš, additional, and Šutovská, Martina, additional

Published
2022
Full Text
View/download PDF

11. Evaluating Thromboprophylaxis Strategies for High-Risk Pregnancy: A Current Perspective.

Author

Stančiaková, Lucia, Brisudová, Kristína, Škorňová, Ingrid, Bolek, Tomáš, Samoš, Matej, Biringer, Kamil, Staško, Ján, and Sokol, Juraj

Subjects
HIGH-risk pregnancy, PREGNANT women, CESAREAN section, THROMBOEMBOLISM, FAMILY history (Medicine), SCIENCE databases
Abstract

Venous thromboembolism (VTE) represents one of the leading causes of death during pregnancy. The greatest risk for it is the presence of medical or family history of VTE, stillbirth, cesarean section and selected thrombophilia. Appropriate thromboprophylaxis has the potential to decrease the risk of VTE in at-risk pregnant patients by 60–70%. Based on this, the authors reviewed the PubMed, Web of Science and Scopus databases to identify the possibilities of thromboprophylaxis in pregnant patients with a high risk of VTE. Moreover, they summarized its management in specific situations, such as cesarean delivery or neuraxial blockade. Currently, low-molecular-weight heparins (LMWH) are the preferred drugs for anticoagulant thromboprophylaxis in the course of pregnancy and postpartum due to easy administration and a lower rate of adverse events. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. COVID-19 and the Response to Antiplatelet Therapy

Author

Bolek, Tomáš, primary, Samoš, Matej, additional, Jurica, Jakub, additional, Stančiaková, Lucia, additional, Péč, Martin Jozef, additional, Škorňová, Ingrid, additional, Galajda, Peter, additional, Staško, Ján, additional, Mokáň, Marián, additional, and Kubisz, Peter, additional

Published
2023
Full Text
View/download PDF

32. ROTEM Testing for Direct Oral Anticoagulants

Author

Korpallová, Barbora, additional, Samoš, Matej, additional, Bolek, Tomáš, additional, Kühnelová, Linda, additional, Škorňová, Ingrid, additional, Kubisz, Peter, additional, Staško, Ján, additional, and Mokáň, Marián, additional

Published
2021
Full Text
View/download PDF

38. Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation

Author

Prídavková, Dana, Samoš, Matej, Bolek, Tomáš, Škorňová, Ingrid, Žolková, Jana, Kubisz, Peter, Staško, Ján, and Mokáň, Marián

Subjects
Article Subject
Abstract

Type 2 diabetes (T2D) is an independent risk factor of stroke and systemic embolism in patients with atrial fibrillation (AF), and T2D patients with AF-associated stroke seem to have worse clinical outcome and higher risk of unfavorable clinical course compared to individuals without this metabolic disorder. Long-term anticoagulation is indicated in majority of T2D patients with AF to prevent adverse AF-associated embolic events. Direct oral anticoagulants (DOACs), direct oral thrombin inhibitor dabigatran, and direct oral factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have emerged as a preferred choice for long-term prevention of stroke in AF patients offering potent and predictable anticoagulation and a favorable pharmacology with low risk of interactions. This article reviews the current data regarding the use of DOACs in individuals with T2D and AF.

Published
2019
Full Text
View/download PDF

49. Endothelial Markers in Type 2 Diabetic Patients with Acute Decompensated Heart Failure: A Pilot Study.

Author

Péč MJ, Jurica J, Bolek T, Škorňová I, Péčová M, Cingel M, Horná S, Stančiaková L, Staško J, Tóth Š, Sokol J, Galajda P, Mokáň M, and Samoš M

Abstract

Background: Impaired endothelial function has been associated with vascular complications in type 2 diabetes (T2D), but its role in T2D-related heart failure (HF) remains indeterminate. The aim of this study was to assess selected markers of endothelial function in T2D patients with acute decompensated HF., Methods: A pilot prospective study on patients with acute decompensated HF requiring in-hospital admission was carried out. The vascular endothelial growth factor (VEGF), intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1) were assessed at admission and after decongestion. Subsequently, differences in these markers between T2D and non-diabetic (ND) patients were studied., Results: In total, 39 patients (21 with T2D and 18 ND patients) were enrolled. Twenty-eight patients presented with preserved ejection fraction (EF), and 11 presented with reduced EF. Looking at the VEGF levels in T2D patients, on admission, a median of 233.0 pg/mL (1.7-598 pg/mL) was found compared to 106.0 pg/mL (1.7-888 pg/mL) in ND individuals; the differences reached statistical significance ( p = 0.04). There were no significant differences in VEGF levels after decongestion, and in VCAM-1 (2237 ± 1195 vs. 2699 ± 1093 ng/mL, p = 0.37) and ICAM-1 (596 ± 268 vs. 638 ± 437 ng/mL, p = 0.79) levels between T2D and ND patients upon admission and after decongestion. The value of EF (preserved or reduced) affected the VEGF levels upon admission., Conclusions: This study identified significantly higher VEGF levels upon admission due to acute decompensated HF in T2D patients.

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results